Phase II study of Regorafenib as single agent for the treatment of patients with metastatic colorectal cancer with any RAS or BRAF mutation and previously treated with FOLFOXIRI plus bevacizumab.

Garcia P, Ortiz MJ, Duran G, Falco E, Munoz A, Garcia-Paredes B, Salgado M, Lopez-Ladron A, Vieitez de Prado JM, Valladares M, Salud A, Guillen-Ponce C, Lopez R, Robles L, Juarez A, Serrano S, Montagut C, Zanui M, Gil Raga M, La Casta A, Benavides M, Aranda E.

Ann. Oncol. 2015; 26. FI: 7.040 (Q1).

Correlation between RECIST-conventional imaging techniques, morphologic response by CT and histopathologic response, in hepatic metastasis secondary to colorectal cancer: The AVAMET study.

Vera R, Gomez ML, Ayuso JR, Figueras J, Garcia P, Martinez-Marin V, La Casta A, Ruiz A, Safont MJ, Aparicio J, Campos JM, Camara JC, Martin-Richard M, Montagut C, Pericay C, Vieitez de Prado JM, Falco E, Jorge M, Marin M, Salgado M, GEMCAD.

J. Clin. Oncol. 2015; 33. FI: 18.428 (Q1).

Low disphagia as a form of presentation of a cyst of duplication of cardia.

Aranburu I, Castielle A, Zapata E, Izaguirre E, Elorza JL, Zubiaurre L, Iribarren A, Asensio JI, Larburu S.

Rev. Esp. Enferm. Dig. 2015; 107: 464-465. FI: 1.414 (Q4).

Toxic hepatocellular hepatitis due to labetalol.

Castiella A, Iglesias U, Zapata E, Zubiaurre L, Iribarren A.

Gastroenterol. Hepatol. 2015; 38: 326-327. FI: 0.838 (Q4).

A Clinical-Phusiological comparative study in dofs woth ileoanal pouch anastomosis with and without single and double myotomy.

Ruiz-Montesinos I, Enriquez-Navascués J, Villaverde-Amundarain Y.

Span. J. Surg. Res. 2015; 3: 107-111. FI: 0.000 (Q0).

Bile Acids in Physiology, Pathology and Pharmacology.

Marin JJ, Macias RI, Briz O, Banales JM, Monte MJ.

Curr Drug Metab. 2015; 17: 4-29. FI: 2.976 (Q2).

SNPs in candidate genes MX dynamin-like GTPase and chemokine (C-C motif) receptor-5 are associated with ovine pulmonary adenocarcinoma progression in Latxa sheep.

Larruskain A, Esparza-Baquer A, Minguijon E, Juste RA, Jugo BM.

Anim. Genet. 2015; 46: 666-675. FI: 2.207 (Q1).

SNPs in APOBEC3 cytosine deaminases and their association with Visna/Maedi disease progression.

Esparza-Baquer A, Larruskain A, Mateo-Abad M, Minguijon E, Juste RA, Benavides J, Perez V, Jugo BM.

Vet. Immunol. Immunopathol. 2015; 163: 125-133. FI: 1.535 (Q1).

Characterization and genotyping of the DRB1 gene of the major histocompatibility complex (MHC) in the Marmota monax, animal model of hepatitis B.

Moreno-Cugnon L, Esparza-Baquer A, Larruskain A, Garcia-Etxebarria K, Menne S, Gonzalez-Aseguinolaza G, Jugo BM.

Mol. Immunol. 2015; 63: 505-512. FI: 2.973 (Q2).

Gender and plasma iron biomarkers, but not HFE gene mutations, increase the risk of colorectal cancer and polyps.

Castiella A, Mugica F, Zapata E, Zubiaurre L, Iribarren A, de Juan MD, Alzate L, Gil I, Urdapilleta G, Otazua P, Emparanza JI.

Tumor Biol. 2015; 36: 6959-6963. FI: 3.611 (Q2).